Secretome Therapeutics Appoints Financial Veteran as CFO

Most recently, Deepa Prasad was president and CEO of vTv Therapeutics. Dallas-based Secretome Therapeutics is a biotechnology company developing first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.

Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.

“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement. “Deepa’s history assisting companies in financings, partnerships, and corporate strategy will be invaluable as we advance our therapies into clinical trials, and we are thrilled to have her on our team.”

Prasad has more than 20 years of expertise in finance and operations.

“I am truly excited to be joining Secretome at this pivotal time in the company’s history. I believe that secretomes represent a true breakthrough in the field of cell-based therapy, and I look forward to helping Secretome transform the way we treat diseases,” Prasad said in a statement.

Most recently, she was president and CEO of vTv Therapeutics where she refocused operations, secured the launching of research, and helped raise $35 million in financing. Before that, Prasad was general partner at WestRiver Group where she led healthcare investments in many companies, including Design Therapeutics.

Prasad has also held leadership positions at numerous public and private companies, including Blue Shield, Optum, and Coherus Biosciences. She began her career in biotech investment banking executing private placements and buy-side/sell-side M&A.

She serves on the board of directors at Design Therapeutics and as executive director of the Robinson Life Sciences, Business and Entrepreneurship Program at UC Berkeley.

Secretome Therapeutics’ lead product, STM-21, is a novel secretome in development for adult and pediatric forms of heart failure, and the company’s pipeline includes novel secretomes in development for neurodegenerative and dermatological diseases.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • Plano ISD partners with Capital One for the Savings Success program to take some of the myths out of money and turn them into financial facts.

  • Southlake-based Renibus Therapeutics—a clinical-stage biotech company developing innovative products for cardiorenal diseases—has received $33 million in bridge financing to help it advance three drugs in its pipeline. The drugs are currently in various phases of trials.

  • The Cancer Prevention & Research Institute of Texas has provided more than $3.1 billion in funding toward the development of cancer-fighting therapeutics, devices, diagnostics, and tools since 2010. It's now issued a call for startups and early-stage companies to apply for product development research grants for the 2023 fiscal year. “CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention,” CEO Wayne Roberts said last May.

  • Dallas' Secretome Therapeutics Appoints Board Director, Assembles Clinical Advisory Board

    Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure. “I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement. “Secretome Therapeutics’ team, vision, and groundbreaking products have the potential to revolutionize treatment for a wide range of chronic, inflammatory diseases, and I am thrilled to…

  • Westlake-based Charles Schwab has partnered with Girls Scouts USA to modernize and relaunch the organization's financial literacy badges. The new financial literacy curriculum includes topics such as investing basics, building wealth, entrepreneurship, fraud awareness, and budgeting for different goals throughout life. The goal is to help bridge the gap between what girls learn in school and what they need to feel confident managing finances in life and business,.